- 3 Days
- 4 Channels
- 50 EURETINA Sessions
Registration Open Programme Exhibition & Sponsorship Satellite Symposia
Registration Open Programme Exhibition & Sponsorship Satellite Symposia
Please note that all times are in Central European Summer Time (CEST)
Programme Filter
Loading ... please wait11.00
U. Schmidt-Erfurth AUSTRIA
Neovascular AMD: AI evidence on novel grounds
11.06
S. Sivaprasad UK
Diabetic retinopathy severity: Diagnostic and therapeutic guidance
11.12
R. Tadayoni FRANCE
Surgery of (pseudo) holes: Standards in macular surgery
11.18
A. Loewenstein ISRAEL
Heads-up surgery: More options than ever
11.24
TBC
The myopia pandemic: The European response
11.30
Discussion
11.45
End of session
12.00
B. Corcóstegui SPAIN
Encirclement: what does it do? when to use it?
12.05
J. Garcia-Arumi SPAIN
PVR, when how and what to peel
12.10
T. Williamson UK
Retinectomy in PVR: early vs late
12.15
J.C. Pastor SPAIN
Risks with Tamponade agents
12.20
TBC
Realistic expectations in complex RRD
12.25
Discussion
12.45
End of session
14.00
E. Pilotto ITALY
Retinopathy in Type 1 diabetic children
14.06
A. Fawzi USA
Retinal blood flow in diabetic retinopathy
14.12
M. Paques FRANCE
Deferred laser in DME: follow ETDRS or aim for TelCaps?
14.18
N. Bressler USA
Current and future DRCRnet protocols in diabetic retinopathy
14.24
A. Laidlaw UK
Surgical solutions for DR, when to go in
14.30
Discussion
14.45
End of session
15.00
P. Keane UK
Artificial Intelligence in OCT and fundus images: Overview
15.07
T. Peto UK
Artificial Intelligence for DR screening
15.11
R. Tadayoni FRANCE
From DRSS to new imaging and AI
15.15
R. Sznitman SWITZERLAND
Biomarker detection in OCT scans
15.19
S. Sadda USA
Deep learning for assessment of AMD biomarkers
15.23
R. Schwartz UK
Using deep learning to detect reticular pseudodrusen on the UK Biobank – results and implications
15.27
Discussion
15.45
End of session
16.00
M. Berrocal PUERTO RICO
Rescue the View
16.01
Discussion
16.04
J. Garcia Arumi SPAIN
Lens Dislocation and Retinal Detachment in Marian Syndrome
16.05
Discussion
16.08
C. Claes BELGIUM
Oops, no way to make sclerotomies
16.09
Discussion
16.12
K. Kadonosono JAPAN
Limiting Phototoxicity During 3D Vitrectomy for Retinitis Pigmentosa
16.13
Discussion
16.16
X. Li CHINA
Air-Fluid Exchange…
16.17
Discussion
16.20
A. Maia BRAZIL
Retinal Detachment with Suprachoroidal Hemorrhage
16.21
Discussion
16.24
G. Pertile ITALY
Subretinal Injection of Membrane Blu Dual
16.25
Discussion
16.28
S. Priglinger GERMANY
Submacular Perfluoron
16.29
Discussion
16.32
S. Rizzo ITALY
Disposable Cryo
16.33
Discussion
16.36
D. Steel UK
Perfluoron Guided Subretinal TPA
16.37
Discussion
16.40
R. Tadayoni FRANCE
TBD
16.41
Discussion
16.45
End of session
08.30
TBC
New insights from epidemiological studies
08.35
A. Tufail UK
Managing AMD patients: impact of AI-based biomarker detection in OCT scans
08.40
R. Guymer AUSTRALIA
Approaches to slow progression of intermediate AMD
08.45
Discussion
08.52
J. Mones SPAIN
Novel therapeutic approaches for neovascular AMD – better efficacy/longer duration?
08.57
C. Regillo USA
Long-acting drug delivery in nAMD: ARCHWAY phase 3 results
09.02
A. Loewenstein ISRAEL
Improving adherence and outcomes in AMD therapy: Home monitoring
09.07
Discussion
09.15
End of session
09.30
R. Schlingemann THE NETHERLANDS
New insights in the pathophysiology of diabetic macular edema in vein occlusion
09.36
P. Lanzetta ITALY
The management of macular edema in vein occlusion
09.42
J. Garcia-Arumi SPAIN
The surgical management of resistant cases of vein occlusion
09.48
F. Bandello ITALY
Is OCT-A essential in vein occlusion?
09.54
U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in vascular retinal disease
10.00
Discussion
10.15
End of session
10.30
B. Bodaghi FRANCE
Viral retinitis
10.36
A. Adan SPAIN
New strategies with biologics in uveitis
10.42
F. Pichi UNITED ARAB EMIRATES
OCTA in uveitis
10.48
J. van Meurs THE NETHERLANDS
Earlier antibiotic treatment is the most feasible step to improve treatment of endophthalmitis
10.54
J. Garcia-Arumi SPAIN
Surgical treatment of endophthalmitis
11.00
Discussion
11.15
End of session
13.45
R. Finger GERMANY
AMD risk and progression.
13.52
A. Schuster GERMANY
Glaucoma onset and progression
13.59
T. Peto UK
Diabetic eye diseases (DR & DME) onset, development of treatable stages, visual prognosis
14.06
C. Delcourt FRANCE
Diet and eye disease
14.13
Discussion
14.30
End of session
15.45
Impact of COVID on Retina Care: the aftermath
Panel
A. Tufail UK
A. Lowenstein Israel
F. G. Holz GERMANY
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
C. Mariotti ITALY
L. Kodjikian FRANCE
J. Francois Korobelnik FRANCE
15.54
How does safe spacing/PPE affect the delivery of care – can we continue to be cost-effective?
Panel
R. Hamilton UK
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
J. Francois Korobelnik FRANCE
16.03
Should we alter our surgical environment?
Panel
R. Tadayoni FRANCE
A. Laidlaw UK
F. G. Holz GERMANY
J. Garcia-Arumi SPAIN
C. Mariotti ITALY
16.12
Is virtual the new reality? The Good, the Bad and the Ugly – Efficiency of virtual consults, conferences, and teaching
Panel
F. G. Holz GERMANY
A. Lowenstein Israel
A. Tufail UK
R. Tadayoni FRANCE
E. Midena ITALY
16.21
What have we learned from the COVID-disruption that we should keep?
Panel
F. G. Holz GERMANY
A. Lowenstein Israel
A. Tufail UK
S. Wolf SWITZERLAND
16.30
End of session
16.45
M. Michaelides UK
Phase 1/2 Clinical Trial of AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 9-month Results
16.50
F. G. Holz GERMANY
Zimura A Novel C5 Inhibitor, Significantly Reduces the Mean Rate of Geographic Atrophy Growth in the GATHER1 Clinical Trial
16.55
R. Tadayoni FRANCE
Oculis OCS-01 Phase 2 Study Results: A Topical Therapeutic for DME
17.00
R. Avery USA
RGX-314 Gene Therapy: Ongoing Phase I/IIa Interim Results
17.05
S. Sadda USA
Impact of pegcetocoplan on progression of nascent geographic atrophy in AMD
17.10
R. Tadayoni FRANCE
Investigating adverse events of intraocular inflammation with retinal vasculitis and/or retinal vascular occlusion in patients treated with brolucizumab
17.15
S. Khan UK
A Global Review of Publicly Available Datasets for Ophthalmic Imaging: Recognising Barriers to Access, Usability and Generalisability
17.20
G. Staurenghi ITALY, S. Charles USA, P. Keane UK
Innovation Discussions: 2020 News and Innovation in imaging, surgery, artificial intelligence
17.30
End of session
09.30
C. C.W. Klaver THE NETHERLANDS
New insights in retinal disease derived from the EyeRisk study
09.37
TBC
Lessons learnt from single cell transcriptomics of the retina
09.44
TBC
Vascular-Glia-Neuron interactions in the retina
09.51
C. Sanchez THE NETHERLANDS
From screen to bedside: how to implement AI in the management of retinal disease?
09.58
Discussion
10.15
End of session
10.30
K. Ohno-Matsui JAPAN
Ultra wide-field imaging of pathologic myopia
10.36
X. Li CHINA
Transmissions of OCT in PIC, PIC-CNV and M-CNV
10.42
L. Lu CHINA
Three years outcome of macular buckling for macularhole and foveoschisis in high myopic eyes
10.48
Y. Ikuno JAPAN
Surgical approach for myopic macular diseases
10.54
T. Ho TAIWAN
Thinking processes and practices in the management of vitreoretinal interface disorders in pathologic myopia
11.00
Discussion
11.15
End of session
10.45
D. Sarraf USA
PAMM VS AMN: Brothers in Arms or Strangers in the Night
10.51
S. Sadda USA
PEVAC
10.57
R. Schlingemann THE NETHERLANDS
Retinal vascular abnormalities associated with leakage and hard exudates, Telcaps and others
11.03
B. Leroy BELGIUM
Decision making in rare hereditary retinal disease
11.09
T. Wolfensberger SWITZERLAND
Surgical challenge-subject TBD
11.15
Discussion
11.30
End of session
12.30
C. Maschi FRANCE
Diagnosis and treatment of peripheral exudative haemorrhagic chorioretinopathy
12.35
H. Annas THE NETHERLANDS
Retinal Hemeangiomas – new insights in genetics
12.39
R. Hussain UK
PDT for choroidal haemangioma – long-term outcomes and treatment of recurrent exudative retinopathy
12.43
Discussion
12.50
E. Midena ITALY
Challenges in radiation induced macula oedema
12.54
H. Heimann UK
Photodynamic therapy of choroidal melanoma
12.58
E. Kilic THE NETHERLANDS
Molecular genetics and clinical implications in uveal melanoma
13.02
TBC
Treatment of Metastatic Uveal Melanoma
13.07
Discussion
13.15
End of session
Prof. Frank G. Holz, FEBO, FARVO
University Eye Hospital Bonn
EURETINA President
Dear Colleagues,
We are delighted to announce EURETINA 2020 Virtual, taking place from 2-4 October, and delivering the highest quality scientific content curated by world-renowned experts in the field of retina.
The Virtual Congress will present up to 4 Channels of scientific content, to include EURETINA Sessions & Keynotes on Channel 1, International Symposia on Channel 2, Instructional Courses on Channel 3, as well as a fourth Channel running on Saturday to present the highest scoring Free Papers.
Having extensively researched the most favourable and engaging formats for this new digital landscape, session times have been reduced to 45 minutes, to present engaging, shortened presentations with live discussion throughout.
The virtual Congress will also present a virtual Exhibition, as well as virtual Networking Lounges and the usual programme of industry sponsored Satellite Symposia. We are most grateful to our loyal sponsors for their support in this new endeavour and are glad to be able to still have the opportunity to engage directly with them during the annual meeting.
We very much hope that you will join us at this year’s first virtual EURETINA Congress and encourage you to avail of the reduced registration rates until September 25th.
With very best wishes,
Prof. Frank G. Holz, FEBO, FARVO
President, EURETINA
Do you have a VAT number? If so, please contact registration@euretina.org for information on how to register. Please also contact us if you are a registered business located outside of the EU.
If you are an EURETINA Member or have submitted an abstract, you may already have an account.
If you do not know the login details for this account, please click on the ‘Forgot password’ link on the registration page and they will be sent to you. Alternatively, contact the Registration Department.
| Prices are in Euro & listed without VAT VAT is charged at 20% |
EARLY FEE 5 Aug – 25 Sept |
LATE FEE 26 Sept – 4 Oct |
| EURETINA Member | 50 | 65 |
| Non – Member | 95 | 110 |
| Ophthalmic Nurse / Technician* | 50 | 65 |
*Documentation such as a work ID or verification letter from your hospital is required and must be uploaded during the registration process for approval.Registration Information
EURETINA Lecture Richard Spaide USA
Kreissig LectureMarta S. FigueroaSPAIN
Gisbert Richard Lecture Stanislao RizzoITALY
European Society of Retina SpecialistsTemplehouse, Temple Road,Blackrock, Co Dublin, A94 Y5W5
Phone:+353 1 2100092
Email: euretina@euretina.org
